$RVMD

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

Guggenheim maintained a Buy rating and $275 price target on Revolution Medicines (NASDAQ:RVMD) after the European Medicines Agency recommended approval of its drug Rasonque. The stock has risen 281% in the past year, though some analysts suggest it may be overvalued. Multiple firms have recently initiated coverage with positive ratings and price targets ranging from $226 to $318.

The EU drug regulator's expert panel endorsed six new medicines and five label expansions in October 2026, benefiting Eli Lilly, Pfizer, and Johnson & Johnson. Lilly's weight loss pill Foundayo and Pfizer's breast cancer therapy Tukysa received positive opinions. Johnson & Johnson's cancer therapy Talvey was recommended for an indication extension. Other companies like Ionis, Regeneron, and Revolution Medicines also received positive opinions for their respective drugs.

Jefferies analysts highlighted Oncorus (ONC), Revolution Medicines (RVMD), and Alnylam Pharmaceuticals (ALNY) as top mid-cap biotech stocks ahead of earnings. ONC received a $410 price target, RVMD is expected to exceed revenue estimates, and ALNY's target was lowered to $250. The firm cited specific catalysts and data for each company.

William Blair initiated coverage on Revolution Medicines (RVMD) with an Outperform rating and a $226 price target. The stock has gained 281% over the past year. The FDA approved Rasonque (daraxonrasib) for pancreatic cancer, with trials showing improved survival rates. Analysts cite strong early launch trends and commercial potential, though some note overvaluation. Multiple firms raised price targets following the approval.

Revolution Medicines (RVMD) and Oruka Therapeutics (ORKA), both biotech companies, have outperformed the Magnificent Seven tech stocks this year. RVMD's Rasonque drug received approval for pancreatic cancer treatment, with analysts projecting $15.1B in sales by 2034. ORKA's ORKA-001 shows promise for plaque psoriasis. Both stocks have high upside potential according to Wall Street, but also carry significant risks.

Revolution Medicines' (RVMD) RASONQUE showed a 60% reduction in death risk vs. chemotherapy in a Phase 3 trial for pancreatic cancer. The EMA's CHMP gave a positive opinion for its use in the EU. The drug is already FDA-approved in the U.S.

Global cancer drug spending reached $252B in 2024 and is forecast to exceed $400B by 2028, with the U.S. accounting for 46%. Several companies, including Oncolytics Biotech (ONCY), Revolution Medicines (RVMD), Eli Lilly (LLY), Genmab (GMAB), and Exelixis (EXEL), are advancing treatments for colorectal and pancreatic cancers. Oncolytics reported accelerating enrollment in a colorectal cancer study, while Revolution Medicines received FDA approval for a pancreatic cancer drug.

Revolution Medicines, Inc. (RVMD) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under Item 8.01 below under the heading “Royalty Pharma Tranche A Loan” is incorporated by reference into this Item 2.03. Item 8.

Revolution Medicines' shares fell 6% after FDA documents suggested its pancreatic cancer drug Rasonque may be less effective in certain patients. Zealand Pharma's petrelintide showed weight loss and blood sugar reductions in a Phase 2 trial, but analysts found the blood sugar results underwhelming. Pfizer's Tukysa gained FDA approval for frontline breast cancer treatment. Ultragenyx sold a regulatory voucher for $210M, strengthening its balance sheet.